Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam
|
|
- Suzan Wade
- 5 years ago
- Views:
Transcription
1 AAC Accepted Manuscript Posted Online 14 March 2016 Antimicrob. Agents Chemother. doi: /aac Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates Deanna J. Buehrle 1, Ryan K. Shields 2,3, Liang Chen 4, Binghua Hao 3, Ellen G Press 2, Ammar Alkrouk 2, Brian A. Potoski 1, Barry N. Kreiswirth 4, Cornelius J. Clancy 2,3,5*, M. Hong Nguyen 2,3 1 Department of Pharmacy & Therapeutics, University of Pittsburgh, Pittsburgh, Pennsylvania 2 Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 3 XDR Pathogen Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 4 Rutgers University-New Jersey Medical School, Newark, New Jersey 5 VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania Keywords: Pseudomonas aeruginosa; ceftazidime-avibactam; ceftolozane-tazobactam, carbapenem-resistant Running Title: New β-lactam/β-lactamase inhibitors against P. aeruginosa *Corresponding Author: Cornelius J. Clancy, MD Associate Professor of Medicine University of Pittsburgh 3550 Terrace Street S867 Scaife Hall Pittsburgh, PA Phone: (412) Fax: (412) cjc76@pitt.edu 1
2 30 ABSTRACT We compared ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime, cefepime and piperacillin-tazobactam minimum inhibitory concentrations (MICs) against 38 meropenemresistant P. aeruginosa. No isolates harbored carbapenemases; 74% were OprD mutants. Ceftazidime-avibactam and ceftolozane-tazobactam were active against 92%, including 80% that were resistant to all three β-lactams. Forty-three percent of ceftazidime-avibactam and 6% of ceftolozane-tazobactam-susceptible isolates exhibited MICs at respective breakpoints. Ceftolozane-tazobactam and ceftazidime-avibactam are therapeutic options against meropenemresistant P. aeruginosa infections, which should be used judiciously to preserve activity. 53 2
3 Pseudomonas aeruginosa has a remarkable propensity to develop antibiotic resistance (1). β-lactam resistance in P. aeruginosa is mediated through several mechanisms, including β- lactamase production, altered membrane permeability, MexA-MexB-OprM efflux pump overexpression, and penicillin-binding protein alterations. Inducible extended-spectrum AmpC cephalosporinases may confer reduced susceptibility to all cephalosporins (2, 3). Carbapenems are stable to AmpC cephalosporinases alone, but activity may be attenuated by combinations of Ambler class A or B β-lactamases, AmpC production, efflux pump up-regulation, and OprD porin mutations (4, 5). Carbapenem-resistant P. aeruginosa are often resistant to antipseudomonal agents like ceftazidime, cefepime and piperacillin-tazobactam (6). Avibactam, a new non-β-lactam β-lactamase inhibitor, inactivates extended-spectrum β- lactamases (ESBLs), AmpC cephalosporinases, and class A (including K. pneumoniae carbapenemases (KPC)), class C, and some class D β-lactamases (7). Ceftazidime-avibactam, an agent recently approved by the United States Food and Drug Administration (FDA), shows promising activity against carbapenem-resistant Enterobacteriaceae (CRE) like KPC-producing K. pneumoniae and E. coli. Carbapenemase production is the primary determinant of carbapenem resistance among CRE. Ceftazidime-avibactam is less certain to be active against carbapenem-resistant P. aeruginosa since resistance mechanisms are multifactorial. Ceftolozane, a novel cephalosporin, has less affinity for hydrolysis by Amp C cephalosporinases, is a weak substrate for drug efflux systems, and is not affected by OprD loss (4, 8-10). The addition of the β-lactamase inhibitor tazobactam broadens the activity of ceftolozane to include most ESBLproducing Gram negative bacilli (11). In this study, we measured ceftazidime-avibactam and ceftolozane-tazobactam activity in vitro against meropenem-resistant P. aeruginosa isolates that 3
4 76 77 exhibited a range of susceptibility and resistance to ceftazidime, cefepime and piperacillin- tazobactam Bloodstream (n=20) and respiratory tract (n=18) isolates were collected from unique patients at the University of Pittsburgh Medical Center. Minimum inhibitory concentrations (MICs) of all agents except ceftolozane-tazobactam were determined in triplicate by reference broth microdilution methods (12). Avibactam was tested at a fixed concentration (4 μg/ml). Ceftolozane-tazobactam MICs were measured by Etest according to manufacturer s recommendations (Biomerieux). MICs were interpreted using CLSI reference breakpoints for ceftazidime, cefepime, piperacillin-tazobactam and meropenem; isolates classified as intermediate or resistant by CLSI criteria were defined as resistant. FDA-approved susceptibility breakpoints of 4 µg/ml and 8 µg/ml were applied for ceftolozane-tazobactam and ceftazidime-avibactam, respectively. E. coli ATCC and P. aeruginosa ATCC were used for quality controls. Polymerase chain reaction (PCR) was used to detect Amber class A (TEM, SHV, CTX-M, GES, PER, VEB and KPC), class B (metallo β-lactamases VIM, IMP, NDM), class C (CMY, MOX, FOX, ACT, DHA) and class D (OXA) β-lactamases. OprD mutations were detected by PCR and DNA sequencing. The contribution of efflux to ceftazidime-avibactam and ceftolozane-tazobactam resistance was assessed with the efflux pump inhibitor carbonyl cyanide m-chlorophenyl hydrazine (CCCP) at a fixed concentration of 12.5 µg/ml. Comparisons between categorical or continuous variables were made by Fisher's exact and Mann-Whitney tests, respectively We tested 38 meropenem resistant-p. aeruginosa isolates [Table 1]. None of the isolates harbored class A, B, C or D β-lactamases. Seventy-four percent (28/38) of isolates carried oprd mutations compared to reference strain PAO1, including non-synonymous mutations (34%, 4
5 /38), premature stop codons (13%, 5/38), absence of oprd (11%, 4/38), and various point mutations (9%, 6/38) Sixty-six percent (25/38), 55% (21/38) and 47% (18/38) of isolates were resistant to piperacillin-tazobactam, ceftazidime and cefepime, respectively [Table 1]. Eighteen percent (7/38), 16% (6/38) and 39% (15/38) of isolates were resistant to 1, 2 or 3 of these agents, respectively. Twenty-six percent (10/38) of isolates were susceptible to all three agents. Median ceftazidime-avibactam and ceftolozane-tazobactam MICs were 4 µg/ml (range: 1 to >32) and 1 µg/ml (range: 0.25 to 64), respectively (p<0.0001). MIC 90 s of ceftazidimeavibactam and ceftolozane-tazobactam were 8 µg/ml and 4 µg/ml, respectively. Ceftazidimeavibactam and ceftolozane-tazobactam MICs were strongly correlated (Spearman R=0.91, p < ). Ceftazidime-avibactam and ceftolozane-tazobactam MICs were moderately to strongly correlated with MICs of cefepime, ceftazidime, piperacillin-tazobactam (R range: 0.86 to 0.93 and 0.84 to 0.98, respectively) [Table 2]. Median ceftazidime-avibactam and ceftolozanetazobactam MICs were higher against isolates that were resistant to cefepime, ceftazidime and piperacillin-tazobactam than against susceptible isolates [Table 2]. Median ceftazidimeavibactam and ceftolozane-tazobactam MICs increased as the number of inactive antipseudomonal drugs increased [Figure 1]. Ceftazidime-avibactam and ceftolozane-tazobactam MICs did not correlate with meropenem MICs (R=0.06 and 0.02, respectively; p=0.70 and 0.91, respectively). Eight percent (3/38) of isolates were resistant to ceftazidime-avibactam, and 8% (3/38) were resistant to ceftolozane-tazobactam; two isolates were resistant to both agents, and one isolate was resistant to each agent but not the other. Among ceftazidime-avibactam susceptible 5
6 isolates, 43% (15/35) exhibited MICs that were at the susceptibility breakpoint (8 µg/ml). In contrast, 6% (2/35) of isolates susceptible to ceftolozane-tazobactam exhibited MICs at the susceptibility breakpoint (4 µg/ml) (p=0.0005, 15/35 vs 2/35). Overall, 47% (18/38) and 13% (5/38) of isolates exhibited ceftazidime-avibactam and ceftolozane-tazobactam MICs that were their respective breakpoints (p=0.003). All isolates that were resistant to either ceftazidime-avibactam or ceftolozane-tazobactam were also resistant to all 3 β-lactam agents. Ceftazidime-avibactam MICs were susceptibility breakpoint against 0% (0/10), 57% (4/7), 67% (4/6) and 67% (10/15) of isolates that were resistant to none, one, two and three β-lactam agents, respectively [Figure 1]. The corresponding rates for ceftolozane-tazobactam MICs susceptibility breakpoint were 0% (0/10), 0% (0/7), 0% (0/6) and 33% (5/15) of isolates, respectively [Figure 1]. Isolates resistant to 2 β-lactams were significantly more likely to exhibit MICs breakpoint for ceftazidime-avibactam 67% (14/21) than ceftolozane-tazobactam (24% (5/21) (p=0.03)). Isolates resistant to three β-lactams were also more likely to exhibit MICs breakpoint for ceftazidime-avibactam (67% (10/15)) than ceftolozane-tazobactam (33% (5/15); p=0.14). Sixty-four percent (18/28) and 30% (3/10) of oprd mutants and wild-type isolates were resistant to cefepime (p=0.08), respectively; 57% (16/28) and 20% (2/10), respectively, were resistant to ceftazidime (p=0.07). There was no difference in piperacillin-tazobactam resistance among oprd mutant (71%, 20/28) and wild-type isolates (50%, 5/10; p=0.26). There were also no differences in ceftazidime-avibactam and ceftolozane-tazobactam MICs or resistance rates among oprd mutant and wild-type isolates. 6
7 To assess efflux, we tested all isolates that were resistant to ceftazidime-avibactam and ceftolozane-tazobactam, as well as randomly selected susceptible isolates. The median fold change in MIC against ceftazidime-avibactam was 0 (range: 0 2) with the addition of CCCP, which did not differ between resistant (n=3) or susceptible (n=4) isolates. Likewise, among ceftolozane-tazobactam resistant (n=3) or susceptible (n=4) isolates, MICs were not significantly reduced in combination with CCCP (median 0-fold change, range: 0 2). To our knowledge, this is the first study to compare in vitro activities of ceftazidimeavibactam and ceftolozane-tazobactam against P. aeruginosa clinical isolates. Our most encouraging finding was that each agent was active against 92% (35/38) of meropenem-resistant P. aeruginosa, including 80% (12/15) of isolates that were resistant to all three anti-pseudomonal β-lactams. Overall, at least one of the new agents retained activity against 92% (23/25), 90% (19/21) and 89% (16/18) of isolates that were resistant to piperacillin-tazobactam, ceftazidime and cefepime, respectively. At the same time, our data provide important cautionary notes. Resistance rates to ceftazidime-avibactam and ceftolozane-tazobactam were 8% (3/38), prior to the introduction of these agents to our hospital. Moreover, ceftazidime-avibactam and ceftolozane-tazobactam MICs correlated with each other and with ceftazidime, cefepime and piperacillin-tazobactam MICs, consistent with some degree of cross-resistance. MICs of both ceftazidime-avibactam and ceftolozane-tazobactam were significantly higher as isolates became resistant to more β-lactams. These results corroborate recent reports of decreased susceptibility to ceftazidime-avibactam and ceftolozane-tazobactam among P. aeruginosa isolates that are resistant to other β-lactams, compared with isolates that are susceptible (3) (13) (14) (15). Taken together, the data demonstrate that ceftazidime-avibactam and ceftolozane-tazobactam are 7
8 important additions to the antimicrobial armamentarium, but suggest that they will need to be used judiciously to preserve their activity Our data suggest that ceftolozane-tazobactam may be more active than ceftazidimeavibactam against meropenem resistant-p. aeruginosa. Isolates were significantly more likely to exhibit MICs susceptibility breakpoint for ceftazidime-avibactam than ceftolozane-tazobactam. In particular, significantly higher percentages of isolates that were resistant to 2 antipseudomonal β-lactams exhibited MICs ceftazidime-avibactam breakpoint than the ceftolozane-avibactam breakpoint. These results should be interpreted with the understanding that definitive breakpoint MICs have not been determined for either agent. The ceftazidimeavibactam breakpoint, for example, is based on a ceftazidime dosing regimen of 1 g every 8 hours as a 30 minute infusion (12), whereas the drug has been administered as 2 g of ceftazidime and 500 mg of avibactam over 2 hours in clinical trials (16) ( It is also important to appreciate that the superior performance of ceftolozane-tazobactam may reflect the particular resistance mechanisms of our P. aeruginosa isolates. The isolates in this study did not carry ESBLs or carbapenemases, which is consistent with previous reports in the United States (17, 18), and efflux was not a significant contributor to either ceftazidimeavibactam or ceftolozane-tazobactam resistance. On the other hand, a sizeable majority exhibited oprd mutations. Avibactam restores the activity of ceftazidime against Gram-negative bacilli with resistance mediated through ESBLs, class A and some class D β-lactamases, and chromosomal and acquired AmpC class C enzymes (19-22). It s reasonable to hypothesize that avibactam restores susceptibility to ceftazidime through inhibition of AmpC enzymes. Indeed, a recent study showed 91% (31/34) of P. aeruginosa strains with unique AmpC sequences demonstrated restored susceptibility to ceftazidime following the addition of avibactam (23). 8
9 Tazobactam extends the activity of ceftolozane against most class A and some class C β- lactamases, but the combination is less active than ceftazidime-avibactam against ESBL- or KPC-producing Gram negative bacteria. Therefore, the isolates in this study were likely better suited to inhibition by ceftolozane-tazobactam than ceftazidime-avibactam; results may differ at centers where ESBLs or carbapenemases are more prominent. Clinicians must understand susceptibility patterns at their institutions. Since resistance mechanisms among P. aeruginosa are complex and multifactorial, detailed molecular characterization of isolates should be incorporated into future studies of antimicrobial regimens (24). We anticipate that ceftolozane-tazobactam will be most useful at our center against infections that are caused by P. aeruginosa resistant to carbapenems and all β-lactams, as the agent is likely to be more active than ceftazidime-avibactam and less toxic than colistin or gentamicin. We anticipate that ceftazidime-avibactam will be most useful against infections caused by CRE, for which β-lactamases and carbapenemases are predominant resistance determinants. Indeed, ceftazidime-avibactam was more active against ESBL- and KPCproducing, carbapenem-resistant K. pneumoniae from our center (range: to 4 µg/ml), than reported here against meropenem-resistant P. aeruginosa (range: 1 to > 32 µg/ml) (25). Further studies are needed to understand how ceftolozane-tazobactam and ceftazidime-avibactam can be best incorporated into clinical practice, in a manner that optimizes effectiveness while minimizing the emergence of resistance
10 209 Acknowledgements This project was supported by funding provided to the XDR Pathogen Laboratory by the University of Pittsburgh Medical Center, and by the National Institutes of Health (NIH) under award numbers K08AI (R. K. S.) and R21AI (C. J. C.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Downloaded from on October 29, 2018 by guest 10
11 References 1. Zilberberg MD, Shorr AF Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to J Hosp Med 8: Rodriguez-Martinez JM, Poirel L, Nordmann P Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53: Winkler ML, Papp-Wallace KM, Hujer AM, Domitrovic TN, Hujer KM, Hurless KN, Tuohy M, Hall G, Bonomo RA Unexpected Challenges in Treating Multidrug-Resistant Gram-Negative Bacteria: Resistance to Ceftazidime-Avibactam in Archived Isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 59: Castanheira M, Mills JC, Farrell DJ, Jones RN Mutation-driven beta-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals. Antimicrob Agents Chemother 58: Castanheira M, Deshpande LM, Costello A, Davies TA, Jones RN Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during in 14 European and Mediterranean countries. J Antimicrob Chemother 69: Morrow BJ, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, Peterson J, Davies TA Activities of carbapenem and comparator agents against contemporary US Pseudomonas aeruginosa isolates from the CAPITAL surveillance program. Diagn Microbiol Infect Dis 75:
12 Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Reville TF, Lahiri S, Thresher J, Livchak S, Gao N, Palmer T, Walkup GK, Fisher SL Kinetics of avibactam inhibition against Class A, C, and D beta-lactamases. J Biol Chem 288: Bulik CC, Christensen H, Nicolau DP In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. Antimicrob Agents Chemother 54: Livermore DM, Mushtaq S, Ge Y, Warner M Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int J Antimicrob Agents 34: Juan C, Zamorano L, Perez JL, Ge Y, Oliver A, Spanish Group for the Study of P, Spanish Network for Research in Infectious D Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 54: Bulik CC, Tessier PR, Keel RA, Sutherland CA, Nicolau DP In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms. Antimicrob Agents Chemother 56: Institute CaLS Performance standards for antimicrobial susceptibility testing (M100-S24). Clinical and Laboratory Standards Institute, Wayne, PA. 13. Tato M, Garcia-Castillo M, Bofarull AM, Canton R, Group CS In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study. Int J Antimicrob Agents 46:
13 Sutherland CA, Nicolau DP Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals. Clin Ther 37: Sader HS, Castanheira M, Mendes RE, Flamm RK, Farrell DJ, Jones RN Ceftazidimeavibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and Antimicrob Agents Chemother 59: Sader HS, Castanheira M, Flamm RK, Farrell DJ, Jones RN Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in Antimicrob Agents Chemother 58: Fehlberg LC, Xavier DE, Peraro PP, Marra AR, Edmond MB, Gales AC Beta-lactam resistance mechanisms in Pseudomonas aeruginosa strains causing bloodstream infections: comparative results between Brazilian and American isolates. Microb Drug Resist 18: Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, Van Bambeke F Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 13: Aktas Z, Kayacan C, Oncul O In vitro activity of avibactam (NXL104) in combination with beta-lactams against Gram-negative bacteria, including OXA-48 beta-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 39: MacVane SH, Crandon JL, Nichols WW, Nicolau DP In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates. Antimicrob Agents Chemother 58:
14 Hall JM, Corea E, Sanjeewani HD, Inglis TJ Molecular mechanisms of beta-lactam resistance in carbapenemase-producing Klebsiella pneumoniae from Sri Lanka. J Med Microbiol 63: Castanheira M, Costello SE, Woosley LN, Deshpande LM, Davies TA, Jones RN Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii- Acinetobacter calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean countries and detection of two novel beta-lactamases, GES-22 and VIM-35. Antimicrob Agents Chemother 58: Lahiri SD, Johnstone MR, Ross PL, McLaughlin RE, Olivier NB, Alm RA Avibactam and class C beta-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance. Antimicrob Agents Chemother 58: Quale J, Bratu S, Gupta J, Landman D Interplay of efflux system, ampc, and oprd expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 50: Shields RK, Nguyen MH, Potoski BA, Press EG, Chen L, Kreiswirth BN, Clarke LG, Eschenauer GA, Clancy CJ Doripenem MICs and ompk36 Porin Genotypes of Sequence Type 258, KPC- Producing Klebsiella pneumoniae May Predict Responses to Carbapenem-Colistin Combination Therapy among Patients with Bacteremia. Antimicrob Agents Chemother 59:
15 Table 1. In vitro susceptibility data on 38 meropenem-resistant P. aeruginosa isolates Antimicrobial Median MIC MIC 90 Range % Resistance agents (µg/ml) (µg/ml) (µg/ml) Meropenem % Cefepime >512 47% Ceftazidime > % Piperacillintazobactam > % Ceftazidimeavibactam >32 8% Ceftolozanetazobactam %
16 Table 2. Correlations between MICs of ceftazidime-avibactam and ceftolozane-tazobactam MICs and those of other β-lactam agents. Cefepime Median ceftazidimeavibactam MIC (µg/ml) Median ceftolozanetazobactam MIC (µg/ml) Susceptible isolates (n=20) Resistant isolates (n=18) 8 2 p-values < Correlation between cefepime and indicated agent 1 Ceftazidime Susceptible isolates (n=17) Resistant isolates (n=21) p-values < Correlation between ceftazidime and indicated agent 1 Piperacillin-tazobactam Susceptible isolates (n=13) Resistant isolates (n=25) 8 1 p-values < Correlation between piperacillintazobactam and indicated agent 1 Correlation between 2 agents were determined using Spearman correlation coefficient R.
17 Figure 1. Correlation between ceftazidime-avibactam (A) and ceftolozanetazobactam (B) MICs against meropenem-resistant P. aeruginosa and the number of inactive β-lactam agents A. B. P=0.05 P=0.56 P=0.003 P=0.70 P=0.29 P= Footnote. Horizontal red lines represent the FDA-proposed susceptibility breakpoint for each agent. Median MICs were compared between isolates resistant to zero, one, two, or three β-lactam agents. P=0.04 P=0.76 P=0.04 P=0.02 P=0.008 P=0.003
In Vitro Activity of Ceftazidime-Avibactam Against Isolates. in a Phase 3 Open-label Clinical Trial for Complicated
AAC Accepted Manuscript Posted Online 21 November 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.01820-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10
More informationActivity of Ceftolozane/Tazobactam Against a Broad Spectrum of Recent Clinical Anaerobic Isolates
AAC Accepts, published online ahead of print on 25 November 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.02253-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. Activity
More informationNightmare Bacteria. Disclosures. Technician Objectives. Pharmacist Objectives. Carbapenem Resistance in Carbapenem Resistance in 2017
Nightmare Bacteria How to Deal with the Reality of Carbapenem-resistant Organisms Disclosures I have no conflicts of interest relative to the content of this presentation Matthew L. Brown, Pharm.D., BCPS
More informationNONFERMENTING GRAM NEGATIVE RODS. April Abbott Deaconess Health System Evansville, IN
NONFERMENTING GRAM NEGATIVE RODS April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic limitations to assessing carbapenem resistance in nonfermenting GNRs Discuss antimicrobial
More informationDetermining the Optimal Carbapenem MIC that Distinguishes Carbapenemase-Producing
AAC Accepted Manuscript Posted Online 8 August 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.00838-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 1 2 Determining the
More informationFrequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia
Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia Helio S. Sader, M.D.* Mariana Castanheira, Ph.D. Rodrigo E. Mendes, Ph.D. Robert K. Flamm, Ph.D. JMI
More informationDoripenem, gentamicin and colistin, alone and in combinations, against. gentamicin-susceptible, KPC-producing Klebsiella pneumoniae strains with
AAC Accepts, published online ahead of print on 24 February 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.01949-13 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 3 Doripenem,
More informationMHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions
MHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions Dr. Andrew Walkty Medical Microbiologist, Diagnostic Services Manitoba (DSM) June. 17,
More informationMechanisms of Resistance to Ceftazidime-Avibactam. Romney M. Humphries, PhD D(ABMM) Chief Scientific Officer Accelerate Diagnostics.
Mechanisms of Resistance to Ceftazidime-Avibactam Romney M. Humphries, PhD D(ABMM) Chief Scientific Officer Accelerate Diagnostics UCLA, January 2015 62 year old woman with advanced pancreatic cancer Vomiting
More informationβ-lactamase inhibitors
β-lactamase inhibitors Properties, microbiology & enzymology DAVID M LIVERMORE Professor of Medical Microbiology, UEA Lead on Antibiotic Resistance, Public Health England β-lactamase classes A B C D Serine
More informationOvercoming the PosESBLities of Enterobacteriaceae Resistance
Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1 Disclosure No
More informationCeftazidime-Avibactam and Aztreonam an interesting strategy to Overcome β- Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae
AAC Accepted Manuscript Posted Online 19 June 2017 Antimicrob. Agents Chemother. doi:10.1128/aac.01008-17 Copyright 2017 American Society for Microbiology. All Rights Reserved. 1 2 3 Ceftazidime-Avibactam
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationAntibiotic Treatment of GNR MDR Infections. Stan Deresinski
Antibiotic Treatment of GNR MDR Infections Stan Deresinski Kucers: The Use of Antibiotics 1st Edition 1972 392 pages Kucers: The Use of Antibiotics 7 th Edition 2017 5338 pages Carbapenem Susceptibility
More informationReporting blood culture results to clinicians: MIC, resistance mechanisms, both?
Reporting blood culture results to clinicians: MIC, resistance mechanisms, both? Christian G. Giske, MD, PhD Senior Consultant Physician/Associate Professor Department of Clinical Microbiology Karolinska
More informationALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella
ALERT Clinical microbiology considerations related to the emergence of New Delhi metallo beta lactamases (NDM 1) and Klebsiella pneumoniae carbapenemases (KPC) amongst hospitalized patients in South Africa
More informationCarbapenem resistance has emerged worldwide in clinical isolates of Enterobacteriaceae. crossm
SUSCEPTIBILITY crossm In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae Meredith A. Hackel, a Olga Lomovskaya, b Michael N. Dudley, b James A. Karlowsky,
More informationCarbapenem-resistant Escherichia coli and Klebsiella pneumoniae in Taiwan
Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae in Taiwan An Infection Control Emergency Speaker: L Kristopher Siu Principal Investigator Division of Infectious Diseases National Institute
More informationRevised AAC Version 2» New-Data Letter to the Editor ACCEPTED. Plasmid-Mediated Carbapenem-Hydrolyzing β-lactamase KPC-2 in
AAC Accepts, published online ahead of print on 3 December 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.01180-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationST11 KPC-2 Klebsiella pneumoniae detected in Taiwan
AAC Accepts, published online ahead of print on 30 January 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.05576-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5
More informationRapid detection of carbapenemase-producing Pseudomonas spp.
JCM Accepts, published online ahead of print on 12 September 2012 J. Clin. Microbiol. doi:10.1128/jcm.01597-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 Rapid detection
More informationUpdate on CLSI and EUCAST
Update on CLSI and EUCAST 1 Completed work» Cephalosporin breakpoints for Enterobacteriaceae ESBL screens MIC versus resistance mechanism» Carbapenem breakpoints for Enterobacteriaceae Modified Hodge Test»
More informationAAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi: /aac
AAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00931-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationPublic Health Surveillance for Multi Drug Resistant Organisms in Orange County
Public Health Surveillance for Multi Drug Resistant Organisms in Orange County Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Public Health Antimicrobial Mechanisms of Action
More informationTreatment Options for Urinary Tract Infections Caused by Extended-Spectrum Β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae
Treatment Options for Urinary Tract Infections Caused by Extended-Spectrum Β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae medicine.missouri.edu/jahm/treatment-options-urinary-tract-infections-caused-extended-spectrum-β-lactamase-producingescherichia-coli-klebsiella-pneumoniae/
More informationJournal of Infectious Diseases and
Journal of Infectious Diseases & Therapy ISSN: 2332-0877 Journal of Infectious Diseases and Therapy Santanirand et al., J Infect Dis Ther 2018, 6:5 DOI: 10.4172/2332-0877.1000378 Research Article Open
More informationReceived 31 January 2011/Returned for modification 2 March 2011/Accepted 15 March 2011
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1965 1969 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.00203-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparative
More informationGuidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011
Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011 Objectives: To discuss the guidelines for detection of CRE in the laboratory setting. To review
More informationEmergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong. Title. Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH
Title Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong Author(s) Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH Citation International Journal Of Antimicrobial Agents, 2011, v. 37 n. 4, p.
More informationAcademic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE
Academic Perspective in Emerging No, we can t Issues treat of carbapenemase Resistance and ESBL in Gram-ve producers Bacteria based on MIC David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic
More informationExpert rules. for Gram-negatives
Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University
More informationDetection of Carbapenem Resistant Enterobacteriacae from Clinical Isolates
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 5 (2016) pp. 864-869 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.505.089
More informationAntibacterial Antibiotic Resistancein 2016 What Should an Internist Know? Disclosures. Objectives 3/6/2016. Achaogen: Allergan:
Antibacterial Antibiotic Resistancein 2016 What Should an Internist Know? Michael Satlin, MD, MS Assistant Professor of Medicine Division of Infectious Diseases Weill Cornell Medicine March 4, 2016 1 Disclosures
More informationNew insights in antibiotic and antifungal therapy in the compromised host
New insights in antibiotic and antifungal therapy in the compromised host Claudio Viscoli University of Genova Ospedale Policlinico San Martino, Genova Potential conflicts of interest (last 5 years) Received
More informationHelen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); July 2014.
Annual survey of extended-spectrum -lactamase (ESBL)-producing Enterobacteriaceae, 2013 Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research
More informationDisclosure. Objectives. Evolution of β Lactamases. Extended Spectrum β Lactamases: The New Normal. Prevalence of ESBL Mystic Program
47 th Annual Meeting August 2-4, 2013 Orlando, FL Extended Spectrum β Lactamases: The New Normal Disclosure I do have a vested interest in or affiliation with the following companies or organizations Triax
More informationChalhoub et al. Avibactam and resistance mechanisms in P. aeruginosa - Page 1 of 17
Chalhoub et al. Avibactam and resistance mechanisms in P. aeruginosa - Page 1 of 17 International Journal of Antimicrobial Agents (IJAA-D-17-00824) Short communication (In press) Loss of activity of ceftazidime-avibactam
More informationNational Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats
National Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats Jean B. Patel, PhD, D(ABMM) Science Lead, Antibiotic Resistance and Coordination Unit Centers for
More informationEmergence of non-kpc carbapenemases: NDM and more
Emergence of non-kpc carbapenemases: NDM and more --- David Livermore Health Protection Agency, UK The first acquired carbapenemase to be recognised in gram-negative bacteria was IMP-1, a metallo-type,
More informationDetecting CRE. what does one need to do?
5 th ICAN Conference, Harare 4 th November 2014 Room 2: 10:30-12:00 Detecting CRE (Carbapenem-resistant Enterobacteriaceae) what does one need to do? Dr Nizam Damani Associate Medical Director Infection
More informationCarbapenem Disks on MacConkey agar as screening methods for the detection of. Carbapenem-Resistant Gram negative rods in stools.
JCM Accepts, published online ahead of print on 7 November 2012 J. Clin. Microbiol. doi:10.1128/jcm.02878-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Carbapenem Disks
More informationA Snapshot of Colistin Use in South-East Europe and Particularly in Greece
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia
More informationSensitive and specific Modified Hodge Test for KPC and metallo-beta-lactamase
JCM Accepts, published online ahead of print on 19 October 2011 J. Clin. Microbiol. doi:10.1128/jcm.05602-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationDiscussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category
Discussion points 2009 CLSI M100 S19 Update Nebraska Public Health Laboratory Changes most important to routine antimicrobial susceptibility testing. Documents available Janet Hindler discussion slide
More informationRapid identification of emerging resistance in Gram negatives. Prof. Patrice Nordmann
Rapid identification of emerging resistance in Gram negatives Prof. Patrice Nordmann Emerging Resistance threats, CDC USA-2013 Enterobacteriaceae producing extendedspectrum β-lactamases (ESBL) Multi-resistant
More informationActivity of tigecycline alone and in combination with colistin and meropenem against carbapenemase
Activity of tigecycline alone and in combination with colistin and meropenem against carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay Spyros Pournaras, Georgia Vrioni, Evangelia
More informationCarbapenemases in Enterobacteriaceae: Prof P. Nordmann Bicêtre hospital, South-Paris Med School
Carbapenemases in Enterobacteriaceae: 2012 Prof P. Nordmann Bicêtre hospital, South-Paris Med School March 21, 2012 Trends in Molecular Medecine NDM IMP OXA-48 KPC VIM ALERT VI M KPC KPC NDM I MP OXA-
More informationCarbapenems and Enterobacteriaceae
Title Carbapenems and Enterobacteriaceae Presenter s details NHLS Dr Khine Swe Swe/Han FC Path ( Micro), SA MMed( micro), SA DTMH(Wits univ),sa PDIC(Stellen univ)sa MB,BS(Yangon),Myanmar Pathologist,Consultant/Lecturer,
More informationCARBAPENEMASE PRODUCING ENTEROBACTERIACEAE
CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE Veroniek Saegeman Veroniek Saegeman UZLeuven Carbapenemase producing Enterobacteriaceae (CPE) Introduction on antibiotic resistance Classification of ß-lactamases
More information(DHA-1): Microbiologic and Clinical Implications
AAC Accepts, published online ahead of print on 20 September 2010 Antimicrob. Agents Chemother. doi:10.1128/aac.00083-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationR EVIEWS OF T HERAPEUTICS
R EVIEWS OF T HERAPEUTICS Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae Sarah Christina Jane Jorgensen, 1 and Michael Joseph Rybak 1,2,3, * 1 Anti-infective
More informationThe Challenge of MDR and XDR infections Friday 14th September, Barcelona Multi-drug and Extremely drug-resistant Pseudomonas aeruginosa
The Challenge of MDR and XDR infections Friday 14th September, Barcelona Multi-drug and Extremely drug-resistant Pseudomonas aeruginosa Juan P. Horcajada Service of Infectious Diseases Hospital del Mar,
More informationSurveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 41 41 Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia IRINA
More informationPhenotypic detection of ESBLs and carbapenemases
Phenotypic detection of ESBLs and carbapenemases Standardized susceptibility testing residential workshop 2016 Katie Hopkins PhD Clinical Scientist Antimicrobial Resistance and Healthcare Associated Infections
More informationTranslocation Studies Mid-Term Review (MTR) Meeting Marseille, France
Marie Curie Actions Research Training Networks (RTN) Translocation Studies Mid-Term Review (MTR) Meeting Marseille, France F. Vidal-Aroca, M.G.P. Page and J. Dreier Background Deteriorating situation regarding
More informationAntibiotic Usage Related to Microorganisms Pattern and MIC
Antibiotic Usage Related to Microorganisms Pattern and MIC DR. Dr. Latre Buntaran Sp.MK(K) Secretary General PERDALIN Head of Compartment of Infection Control PERSI Doripenem: Potent
More informationTreatment Strategies for Infections due to MDR-GNR
Treatment Strategies for Infections due to MDR-GNR Michael Satlin, MD Instructor in Medicine Division of Infectious Diseases Weill Cornell Medical College, New York, NY October 16, 2012 1 2 Faculty Disclosure
More informationActivity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients
ORIGINAL ARTICLE BACTERIOLOGY Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients L. Zamorano 1, C. Juan 1, A.
More information10/4/16. mcr-1. Emerging Resistance Updates. Objectives. National Center for Emerging and Zoonotic Infectious Diseases. Alex Kallen, MD, MPH, FACP
National Center for Emerging and Zoonotic Infectious Diseases Emerging Resistance Updates Alex Kallen, MD, MPH, FACP Lead Antimicrobial Resistance and Emerging Pathogens Team Prevention and Response Branch
More informationFocusing on beta-lactams and beta-lactamase inhibitors
New and Emerging Antibiotics: Data and Practical Recommendations Focusing on beta-lactams and beta-lactamase inhibitors Robert A. Bonomo, M.D. Medical Service, Louis Stokes Cleveland VAMC Department of
More informationIn Vitro Susceptibility Pattern of Cephalosporin- Resistant Gram-Negative Bacteria
In Vitro Susceptibility Pattern of Cephalosporin- Resistant Gram-Negative Bacteria Warunee Punpanich MD*, Worraporn Tantichattanon MD**, Siriporn Wongwatcharapaiboon MD**, Vipa Treeratweeraphong BSc, MSc***
More informationRecommendations for the Management of Carbapenem- Resistant Enterobacteriaceae (CRE) in Acute and Long-term Acute Care Hospitals
Recommendations for the Management of Carbapenem- Resistant Enterobacteriaceae (CRE) in Acute and Long-term Acute Care Hospitals Minnesota Department of Health 11/2011 Infectious Disease Epidemiology,
More informationDownloaded from ismj.bpums.ac.ir at 10: on Friday March 8th 2019
- ( ) - * :... (MDR) (ESBLs: Extended-Spectrum Beta Lactamases). :.. (CLSI:Clinical and Laboratory Standards Institute). ESBL. combined disk method ESBL : / / / / / B / ( /). / / combined disk method.
More informationUse of imipenem. with the support of Wallonie-Bruxelles International. Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles
with the support of Wallonie-Bruxelles International Use of imipenem Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles 1 Β-lactams classification 2 Β-lactams: mode of action Inhibition
More informationEnterobacteriaceae with acquired carbapenemases, 2016
Enterobacteriaceae with acquired carbapenemases, 2016 Background The acquired or transferable (as opposed to chromosomally encoded) carbapenemases found in Enterobacteriaceae belong to three of the four
More informationIn vitro Activity of Ceftolozane-Tazobactam against Recent United States Escherichia coli
JCM Accepts, published online ahead of print on 20 August 2014 J. Clin. Microbiol. doi:10.1128/jcm.02357-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 3 In vitro Activity
More informationComment l EUCAST fixe les concentrations critiques (Breakpoints), Associations inhibiteurs de ß-lactamases et ß-lactamines. Nouvelles molécules
Comment l EUCAST fixe les concentrations critiques (Breakpoints), Associations inhibiteurs de ß-lactamases et ß-lactamines Nouvelles molécules L. Dubreuil Maître de conférences en Pharmacologie Professeur
More informationβ CARBA Test Rapid detection of carbapenemase-producing Enterobacteriaceae strains Contents 1. INTENDED USE
β CARBA Test 25 68260 Rapid detection of carbapenemase-producing Enterobacteriaceae strains 881159 2015/05 Contents 1. INTENDED USE 2. SUMMARY AND EXPLANATION OF THE TEST 3. PRINCIPLE OF THE PROCEDURE
More informationAntibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms
CLINICAL MICROBIOLOGY REVIEWS, Oct. 2009, p. 582 610 Vol. 22, No. 4 0893-8512/09/$08.00 0 doi:10.1128/cmr.00040-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Antibacterial-Resistant
More informationScreening and detection of carbapenemases
Screening and detection of carbapenemases For many isolates with carbapenemases the MICs of carbapenems are around the susceptible breakpoint making resistance difficult to detect - particularly with automated
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationNDA Briefing Document Anti-Infective Drugs Advisory Committee 05 December 2014
CEFTAZIDIME-AVIBACTAM FOR INJECTION for Treatment of Complicated Intra-abdominal Infection (used in combination with metronidazole), Complicated Urinary Tract Infection including Acute Pyelonephritis,
More informationIn vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria
1 2 In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria 3 4 DAVID M LIVERMORE* 1,2, SHAZAD MUSHTAQ 1, MARINA WARNER 1,, ANNA VICKERS 1 AND NEIL WOODFORD 1 5 6 7 8 1 Antimicrobial
More informationRapid detection of carbapenemase-producing Enterobacteriaceae from blood cultures
ORIGINAL ARTICLE BACTERIOLOGY Rapid detection of carbapenemase-producing Enterobacteriaceae from blood cultures L. Dortet 1,L.Brechard 1, L. Poirel 1,2 and P. Nordmann 1,2 1) Service de Bacteriologie-Virologie,
More informationNew Mechanisms of Antimicrobial Resistance and Methods for Carbapenemase Detection
New Mechanisms of Antimicrobial Resistance and Methods for Carbapenemase Detection Stephen G. Jenkins, PhD, F(AAM), D(ABMM) Professor of Pathology and Laboratory Medicine Professor of Pathology in Medicine
More informationHigh Stringency Evaluation of the Automated BD Phoenix CPO Detect and. Running Title: Phenotypic Carbapenemase Detection and Classification
JCM Accepted Manuscript Posted Online 4 October 2017 J. Clin. Microbiol. doi:10.1128/jcm.01215-17 Copyright 2017 Thomson et al. This is an open-access article distributed under the terms of the Creative
More information! 1! PDC Reference ND PDC (1) ( 0.25) PAO1ΔdacB Reference 290 PDC (2) 8 1 (0.5) 1 0.
! 1! TABLE S1 Susceptibility of the selected P. aeruginosa strains to therapeutic antipseudomonal ß-lactams. Strains Origin Sample ampc expression a PDC MIC (µg/ml) b TIC TZP ATM CAZ FEP CZ/T IMP MER Strains
More information/01/$ DOI: /JCM Copyright 2001, American Society for Microbiology. All Rights Reserved.
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2001, p. 183 190 Vol. 39, No. 1 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.1.183 190.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Contemporary
More informationDifferentiation of Carbapenemase producing Enterobacteriaceae by Triple disc Test
Original article: Differentiation of Carbapenemase producing Enterobacteriaceae by Triple disc Test Manish Bansal 1, Nitya Vyas 2, Babita Sharma 3, R.K.Maheshwari 4 1PG Resident, 2 Professor, 3 Assistant
More informationReceived 2 March 2017; returned 27 March 2017; revised 6 April 2017; accepted 10 April 2017
J Antimicrob Chemother doi:10.1093/jac/dkx136 Activity of ceftolozane/tazobactam against surveillance and problem Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles David
More informationSepsis Treatment: Early Identification Remains the Key Issue
Sepsis Treatment: Early Identification Remains the Key Issue Marin H. Kollef, MD Professor of Medicine Washington University School of Medicine Director, Medical Critical Care Director, Respiratory Care
More informationEvaluation of Updated Interpretative Criteria for Categorizing Klebsiella pneumoniae with Reduced Carbapenem Susceptibility
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 2010, p. 4417 4425 Vol. 48, No. 12 0095-1137/10/$12.00 doi:10.1128/jcm.02458-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Evaluation
More informationESCMID Online Lecture Library. by author
www.eucast.org EXPERT RULES IN ANTIMICROBIAL SUSCEPTIBILITY TESTING Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA Departamento de Microbiología II Universidad
More informationNoelisa Montero, MPH. Epidemiologist Consultant. October 19, 2017 Connecticut Department of Public Health Healthcare Associated Infections Program
Carbapenem-resistant Enterobacteriaceae (CRE) in Connecticut: Collaborative Development of a Characterization Panel and Testing of Carbapenemase Genetic Markers, 2017 Noelisa Montero, MPH Epidemiologist
More informationClinical Microbiology Newsletter
Clinical Microbiology Newsletter $88 Vol. 30, No. 10 www.cmnewsletter.com May 15, 2008 Newer β-lactamases: Clinical and Laboratory Implications, Part I * Ellen Smith Moland, B.S.M.T., Soo-Young Kim, M.D.,
More informationjmb Research Article Review Semi Kim 1, Ji Youn Sung 2, Hye Hyun Cho 3, Kye Chul Kwon 1, and Sun Hoe Koo 1 *
J. Microbiol. Biotechnol. (2014), 24(6), 765 770 http://dx.doi.org/10.4014/jmb.1306.06036 Review Research Article jmb Characterization of CTX-M-14- and CTX-M-15-Producing Escherichia coli and Klebsiella
More informationRegional Emergence of VIM producing carbapenem resistant Pseudomonas aeruginosa (VIM CRPA)
National Center for Emerging and Zoonotic Infectious Diseases Regional Emergence of VIM producing carbapenem resistant Pseudomonas aeruginosa (VIM CRPA) Chris Prestel, MD Epidemic Intelligence Service
More informationMultidrug-resistant organisms are a major public health
Improved Phenotype-Based Definition for Identifying Carbapenemase Producers among Carbapenem-Resistant Enterobacteriaceae Nora Chea, Sandra N. Bulens, Thiphasone Kongphet-Tran, Ruth Lynfield, Kristin M.
More information#Corresponding author: Pathology Department, Singapore General Hospital, 20 College. Road, Academia, Level 7, Diagnostics Tower, , Singapore
AAC Accepts, published online ahead of print on 21 October 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.01754-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 Title: Escherichia
More informationGiving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help?
Giving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help? Pranita D. Tamma, M.D., M.H.S. Director, Pediatric Antimicrobial Stewardship Johns Hopkins University School of
More informationMethodological and interpretative problems in antimicrobial susceptiblity tests of P. aeruginosa
Methodological and interpretative problems in antimicrobial susceptiblity tests of P. aeruginosa Y. Glupczynski Laboratoire de bactériologie Cliniques Universitaires UCL de Mont-Godinne Université Catholique
More informationLaboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18
More informationHOW BUGS COMBAT DRUGS: ANTIMICROBIAL RESISTANCE MECHANISMS IN THE MODERN ERA. Romney Humphries, PhD D(ABMM)
HOW BUGS COMBAT DRUGS: ANTIMICROBIAL RESISTANCE MECHANISMS IN THE MODERN ERA Romney Humphries, PhD D(ABMM) Section Chief, UCLA Clinical Microbiology Los Angeles CA rhumphries@mednet.ucla.edu WHAT WE WILL
More informationIn-House Standardization of Carba NP Test for Carbapenemase Detection in Gram Negative Bacteria
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 01 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.701.342
More informationIN VITRO ACTIVITY OF POLYMYXIN B AND MEROPENEM ALONE AND IN COMBINATION AGAINST CARBAPENEM- RESISTANT ENTEROBACTERIACEAE
University of Kentucky UKnowledge Theses and Dissertations--Pharmacy College of Pharmacy 2016 IN VITRO ACTIVITY OF POLYMYXIN B AND MEROPENEM ALONE AND IN COMBINATION AGAINST CARBAPENEM- RESISTANT ENTEROBACTERIACEAE
More informationClinical Management of Infections Caused by Enterobacteriaceae that Express Extended- Spectrum β-lactamase and AmpC Enzymes
56 Clinical Management of Infections Caused by Enterobacteriaceae that Express Extended- Spectrum β-lactamase and AmpC Enzymes Patrick N. A. Harris, BSc, MBBS, MRCP, DTM&H, FRACP, FRCPA 1 1 Infection and
More information(Plasmid mediated) Carbapenemases. Timothy R. Walsh, Cardiff University, Wales
(Plasmid mediated) Carbapenemases Timothy R. Walsh, Cardiff University, Wales What is a carbapenemase? How much carbapenem do they need to breakdown before they are called a carbapenemase? ESBL-enzymes
More informationGlobal Epidemiology of Carbapenem- Resistant Enterobacteriaceae (CRE)
Global Epidemiology of Carbapenem- Resistant Enterobacteriaceae (CRE) Mitchell J. Schwaber, MD MSc Director, National Center for Infection Control Ministry of Health State of Israel November 27, 2012 1
More informationUse of Faropenem as an Indicator of Carbapenemase Activity
JCM Accepts, published online ahead of print on 10 April 2013 J. Clin. Microbiol. doi:10.1128/jcm.00720-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 Use of Faropenem as
More informationControversial Issues in Susceptibility Testing: Point/Counterpoint. April N. Abbott, PhD D(ABMM) Romney M. Humphries, PhD D(ABMM)
Controversial Issues in Susceptibility Testing: Point/Counterpoint April N. Abbott, PhD D(ABMM) Romney M. Humphries, PhD D(ABMM) Disclosures RMH: Funding from BD, biomerieux, Beckman-Coulter, GenMark,
More information